Wancheng Gene

About Wancheng Gene

Wancheng Gene, legally known as Shanghai Wancheng Biotechnology Co., Ltd., is a high-tech enterprise specializing in the research, development, and service of high-throughput single-cell omics. Founded in 2018 by Professor Shi Weiyang, a specialist in developmental biology and functional genomics, and Mr. Wu Ziniu, the company aims to provide integrated solutions for single-cell analysis. Professor Shi, a graduate of Tsinghua University with a Ph.D. from Washington University, has an extensive research background in developmental biology, which fueled his interest in single-cell sequencing. Mr. Wu, also a Tsinghua University biology graduate, brings over two decades of market and sales management experience in the biomedical industry.

The company's core business revolves around its proprietary droplet microfluidics technology platform, which forms the basis for its high-throughput single-cell multi-omics solutions. In May 2021, Wancheng Gene launched its independently developed droplet microfluidic single-cell sequencer, Perseus™, along with配套 chips and reagents. This development was significant as it addressed a gap in domestically produced technology platforms for droplet microfluidic single-cell sequencing in China, aiming to lower both the cost and technical barriers for researchers. The company offers a range of products and services, including single-cell transcriptome sequencing kits, single-cell V(D)J analysis, and the CellCosmo analysis software. Its offerings cater to research in genomics, epigenomics, and other multi-omic studies.

Wancheng Gene serves a diverse client base that includes over two hundred renowned universities, scientific research institutes, hospitals, and corporate enterprises both domestically and internationally. Its business model includes providing comprehensive services such as cell separation, sample processing, library construction, sequencing, and analysis. The company engages in direct sales to top-tier hospitals and collaborates with scientific research service platforms to expand its market reach. The applications for its technology are broad, spanning fields like tumor immunology, companion diagnostics, drug development, and vaccine research. Since its inception, the company has secured multiple funding rounds, including an angel round from CD Capital in January 2019, a Pre-A round of tens of millions of RMB from Northern Light Venture Capital in February 2021, and a Series A round of over 100 million RMB in December 2021.